Key result
NOACs offer safe and effective alternatives to warfarin for stroke prevention in AF.
Why the study?
Do novel oral anticoagulants (dabigatran, rivaroxaban, apixaban) prevent stroke in patients with atrial fibrillation compared to warfarin?
Population
Patients with atrial fibrillation (including nonvalvular AF)
Comparison
Novel oral anticoagulants vs Warfarin
Design
Review
Authors
Loading...
Affirms NOACs as warfarin alternatives in AF; leaves open optimal agent selection and long-term monitoring needs.
Do novel oral anticoagulants (dabigatran, rivaroxaban, apixaban) prevent stroke in patients with atrial fibrillation compared to warfarin?
This review summarizes the evidence supporting the use of novel oral anticoagulants as safe and effective alternatives to warfarin for stroke prevention in atrial fibrillation.
Berman et al. (2013) conducted a review in Atrial Fibrillation. Novel oral anticoagulants (dabigatran, rivaroxaban, apixaban) vs. Warfarin was evaluated. Novel oral anticoagulants, including dabigatran, rivaroxaban, and apixaban, are safe and effective alternatives to warfarin for stroke prevention in patients with atrial fibrillation.